Rapid advances in intensifying upstream processes for biologics production have left
downstream processing as a bottleneck in the manufacturing scheme. Biomanufacturers are …

The economic advantages of continuous processing of biopharmaceuticals, which include
smaller equipment and faster, efficient processes, have increased interest in this technology …

The realization of an end‐to‐end integrated continuous lab‐scale process for monoclonal
antibody manufacturing is described. For this, a continuous cultivation with filter‐based cell …

Scandium-44 (t 1/2= 3.9 h) is a relatively new radioisotope of potential interest for use in
clinical positron emission tomography (PET). Herein, we report, for the first time, the room …

With the advancements in upstream technologies, the capacity for monoclonal antibody
(mAb) production has transformed from a few milligrams to grams per liter. These titers lead …

An integrated all flow-through technology platform for the purification of therapeutic
monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and …

The biopharmaceutical industry is evolving toward process intensification that can offer
increased productivity and improved economics without sacrificing process robustness. A …

Affordability of biopharmaceuticals continues to be a challenge, particularly in developing
economies. This has fuelled advancements in manufacturing that can offer higher …

Achieving consistent product quality of a biotherapeutic is a major target for any
biopharmaceutical manufacturer, even more for a biosimilar producer as comparability with …

Constant flux virus filtration experiments were conducted to evaluate minute virus of mice
retention behavior of four commercial virus filters for continuous bioprocessing applications …